Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | KLN-1010 |
| Trade Name | |
| Synonyms | KLN1010|KLN 1010|KLN 001|KLN-001|KLN001 |
| Drug Descriptions |
KLN-1010 is an envelope-modified lentiviral vector designed to transduce T-cells in vivo and modify them to express a chimeric-antigen receptor (CAR) targeting TNFRSF17 (BCMA), which potentially decreases tumor growth (Cancer Res (2024) 84 (6_Supplement): 48). |
| DrugClasses | TNFRSF17 Immune Cell Therapy 27 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| KLN-1010 | KLN-1010 | 0 | 1 |